RE:RE:RE:RE:RE:Looking for help w/numbers for burn rate, cash on hand, et. Enriquesuave wrote:
"Nice points Cancer Slayer. The N-803 + BCG combo trial is showing about 42% CR at 12 months. 72% of patients achieved a CR at one point and 59% of these maintained a CR rate which equates to 42% overall. It's hard to know how much is attributable to BCG and how much to N-803. Still 15-20 instillations. Very good chance we can beat those numbers, but even if we match we will be a much better option with only 2 instillations. We need a bit more data from Optimized Treatment cohort,and the market will react appropriately IMO"
Agree Enrique. Ooops...a little self-indulgence with my highlighter...hehe.
Yep, all aspects of our ACT are encouraging & patient-friendly. It says a lot when we've been able to achieve the CRs we have despite the fact we only use two treatments & the CR results include prior suboptimal treatment parameters. I also believe the current protocol could also be expanded or utilized (either as a repeat two-treatment process or single treatment) for any who unfortunately relapse in the future...can also be used for TLD 1433-naive patients who had received unsuccessful alternative therapies in the past. TLT's ACT could be a much better option than getting 15+ instillations, or adding combo chemotherapy with all of its adverse effects, or having one's bladder removed.
Perhaps in the near future our ACT can also utilize Rutherrin + x-ray, etc. for both CIS NMIBC & more advance stages of bladder cancer (MIBC). Just so much potential with organometallic medicine, yet so little time for suffering patients. However, I'm feeling more hopeful that our recent alliances can fast track our vast potential into reality. BTW, my hat's off to all of you super longs...both you & patients deserve a huge payday. Continued patience & it will come. JMHO. Good luck...